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Summary Following adjuvant therapy for breast cancer, some patients will die of this tumour while the
remainder will die of other causes. Deaths from breast cancer tend to follow a lognormal distribution, while
deaths from other causes can be approximated by national demographic data. By combining these two
survival models, we have generated an age-specific method for estimating the impact of treatment on overall
long-term survival. Treatment was designed to operate by one of two mechanisms: an increase in cured
fraction, or an increase in median tumour-related survival time among uncured patients. This analysis revealed
that, for young and middle-aged patients, an increase in cured fraction has substantially greater long-term
clinical impact than an increase in median survival time. Unfortunately, the non-parametric tests traditionally
used in prospective clinical trials cannot distinguish between these two mechanisms of action.
In our treatment of patients with cancer, we cannot hope to
prolong life forever. Even those patients who are cured of
their tumour will eventually die from other causes. The best
that we can hope for is to increase survival rate beyond the
level that would have occurred without treatment. By this
logic, it would seem reasonable to judge the relative effective-
ness of treatment by comparing survival rates at a specific
endpoint following diagnosis.
Indeed, such comparison is the express purpose of modern
prospective, randomised clinical trials. Since these trials
demand so much of patients and of society at large, we must
perform our comparisons with the most appropriate statisti-
cal model. The current 'gold standard' for clinical trials
includes a variety of non-parametric methods, such as the log
rank test (Peto et al., 1976 and 1977). These methods are
cherished above all others because their derivations incor-
porate minimal assumptions. Such paucity of assumptions is
achieved by excluding from the model those parameters that
govern tumour-related survival - i.e., likelihood of cure and
median tumour-related survival time among uncured
patients.
It is important to note, however, that cancer treatment is
fundamentally a parametric process: Effective therapy must
increase rate of cure, increase time to death from tumour
among uncured patients, or achieve a combination of these
effects. Thus if we wish to measure precisely the long-term
impact of treatment, we must consider the impact of therapy
on cured fraction and median tumour-related survival
time.
Unfortunately, the survival rate at a specific endpoint is
not always an accurate measure of these two parameters. An
initial advantage in survival rate at five years will vanish with
progressive follow-up if the two treatment groups have the
same cured fraction. An even more dramatic disparity
between short-term and long-term follow-up is shown in
Figure 1, which compares two hypothetical treatment groups.
That group with the longest median survival time has a
higher initial survival rate, while that group with the largest
cured fraction has higher long-term survival rate. Non-
parametric analysis would distinguish the best long-term
therapy only if performed after the curves cross at 10
years.
Figure 1 represents a worst-case scenario, and such cross-
ing of survival curves may be an unlikely event. We are
aware of only one example where such a phenomenon has
been observed in a clinical trial (Cuzick et al., 1987). Never-
theless, non-parametric methods could lead to serious errors
in the analysis of clinical trials: (i) The therapy we select
based on short-term follow-up may enhance only survival
time and thus offer no long-term survival benefit. (ii) Alterna-
tively, we might conclude after limited follow-up that there is
no difference among treatment groups, when in reality one
therapy enhances cured fraction and thus offers a significant
long-term advantage. (iii) When treatment groups differ sub-
stantially in their median survival times, the assumption of
proportional hazards is violated, and this assumption is
incorporated in many non-parametric methods (Peto et al.,
1976 and 1977).
Given both the ambiguity of survival rate at a specific
endpoint and the limitations of non-parametric methods, we
might be tempted to consider only the impact of therapy on
cured fraction. Unfortunately, this approach also poses a
number of problems: (i) The parametric methods used to
estimate cured fraction are complex and have little power
unless available follow-up extends beyond the median value
for tumour-related survival time (Boag, 1949; Gamel et al.,
1990). (ii) Emphasising only cured fraction ignores the
potential clinical benefit to be obtained from prolonging
survival time among uncured patients. (iii) Standard forms of
both parametric and non-parametric analysis fail to reflect
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Figure 1 The relative impact of cured fraction and median
survival time, as demonstrated by two lognormal tumour-related
survival curves. The continuous line represents patients with a
cured fraction of 0.27 and a median survival time of 8.2 years,
while the broken line represents patients with a cured fraction of
0.50 and a median survival time of 3.4 years.
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the important role of patient age at the time oftreatment; for
example, cured fraction will have its greatest impact on the
long-term clinical course of young patients, while older
patients, because of impending death from other causes, may
enjoy only a limited benefit from any therapeutic
modality.
These considerations argue for an index of overall survival
that allows for the impact of patient age and incorporates
both tumour-related deaths and deaths from other causes.
We can apply this index to mathematically generated data to
assess the long-term impact of both treatment and age. Such
analysis may offer important insight into the limitations of
clinical trials for stage 2 breast cancer.
Materials and methods
Tumour-related survival
A survival curve can be generated to represent the likelihood
SB(t) that a patient will not die of breast cancer by time t
following treatment:
SB(t)= C + (1- C ) P(t), where (1)
C = cured fraction, and
P(t) = 1 - D(s) ds,
s = o,.
where D(s) is a function with unit integral that represents the
distribution of time to death from breast cancer. Alterna-
tively, for a log-based distribution, the range of integration
for D(s) becomes s = - co to s = log t (Boag, 1949).
A number of authors have shown that time to death from
many cancers tends to follow a lognormal distribution (Boag,
1949; Mould & Boag, 1975; Mould et al., 1976; Gamel et al.,
1990). The most extensive study to date of breast cancer
(Rutqvist et al., 1984) incorporated 14,731 patients, 5,252 of
whom had stage 2 disease. Using this population, Rutvqist
derived lognormal estimates of basic survival parameters,
including cured fraction (C), mean (M) and standard devia-
tion (S) of log survival time. For patients with stage 2
disease, these values were C= 0.27, M = 1.22, S = 1.04, with
median survival time exp{M} = 3.4 years. Since these patients
were managed in the era before adjuvant therapy, we assume
that these parameters represent the baseline clinical course of
'untreated' patients with stage 2 disease. Using these
parameters in the lognormal model, the tumour-related sur-
vival rate was 53% at 5 years, 38% at 10 years, and 33% at
15 years after diagnosis.
We simulated therapeutic impact by enhancing either cured
fraction or mean log survival time to generate a specific
increase in the survival rate at follow-up intervals of 5, 10,
and 15 years. At each interval, we' used equation (1) to
increase the survival rate from breast cancer by 20% or 40%
(e.g., to 73 and 93% at 5 years). One of two mechanisms was
used to generate this increase:
(i) An increase in C was computed to give the selected
increase in tumour-related survival rate at the selected
follow-up time, keeping M and S constant at the level
observed in 'untreated' patients.
(ii) An increase in M was computed to give the selected
increase in tumour-related survival rate at the selected
follow-up time, keeping C and S constant.
The analysis just described might vary with the particular
function used to represent the distribution of tumour-related
survival times. To test for such variation, we considered both
the loglogit and Weibull distributions, in addition to the
lognormal (Elandt-Johnson & Johnson, 1980). To each log-
normal model, both of these alternative models were fitted by
the least-squared-error technique over the first 15 years of
follow-up. Parallel analysis was then run with all three
models. The results of lognormal analysis are shown in Table
I, while the comparison of loglogit and Weibull models with
the lognormal model is shown in Figure 2.
Survivalfrom other causes
To represent mortality from causes other than breast cancer,
we used all-cause survival data for American women (all
races) in the year 1980 (DHHS, 1985). Since this data base
includes a component of women who died from breast
cancer, an adjustment was made using mortality from breast
cancer for the US population of females (all races) for the
years 1978-1983 (SEER, 1984). For each year of age, mor-
tality from breast cancer was subtracted from mortality due
to all causes. The resulting function SO(a) is assumed to
represent the likelihood that women of any race will survive
all other causes (i.e., all causes excluding breast cancer) to
age a. For women diagnosed as having breast cancer at age
a, the likelihood that they will survive all other causes to time
t following diagnosis is given by SO(a + t)/SO(a).
Survivalfrom all causes
To allow for death from both breast cancer and other causes
among patients with breast cancer, we constructed an index
Table I Median survival time from all causes (MSTAC) as a
function of increases in cured fraction (C) or mean log
tumour-related survival time (M) produced by treatment of patients
with stage 2 breast cancer
Duration of Increased
follow-up survivala Age =35 Age =55 Age= 75
(years) (per cent) C tM C +M 4C +M
0 0 6 6 6 6 5 5
5 20 34 12 18 10 8 7
5 40 47 27 28 20 12 10
10 20 22 13 13 12 7 8
10 40 44 25 25 19 10 10
15 20 18 16 12 14 7 8
15 40 42 29 24 21 9 11
'Tumour-related survival rate of untreated patients is 53% at 5
years, 38% at 10 years, and 33% at 15 years. Percentages shown in
this column represent absolute increases in the tumour-related
survival rate produced at each follow-up interval by increasing either
C (cured fraction) or M (mean log tumour-related survival time) as
the result of hypothetical adjuvant therapy.
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Figure 2 The impact of the specific distribution function used
for survival analysis. Median survival time from all causes
(MSTAC) was computed with the lognormal model as shown in
Table I. These values are plotted against values computed with
the loglogit mode (XXX) and the Weibull model (000). The
straight line represents equivalent values.LONG-TERM SURVIVAL FROM BREAST CANCER 1169
that incorporates both sources ofmortality. For patient's age
a at the time of diagnosis, at time t following diagnosis:
N(a,t) = likelihood of surviving all causes until time t
= SB(t) [SO(a + t)/SO(a)]
T50(a)= t such that N(a,t -1)>0.50 and N(a,t) 0.50,
Thus T50(a) is the median survival time from all causes
(MSTAC) for a patient diagnosed with breast cancer at age a
- i.e., that year following diagnosis during which survival
rate falls below 50%. Note that there is a distinct T50(a) for
each SB(t) generated as described above. For demonstration
purposes, analysis was performed for a = 35, 55, and 75
years.
Results
Figure 1 shows two tumour-related survival curves which
have the same value after ten years of follow-up, despite
substantial differences in cured fraction. From this figure it is
apparent that follow-up at 5 or 10 years is not a reliable
index of long-term survival.
Table I shows the differential impact on MSTAC of inc-
reases in cured fraction (C) versus increases in mean log
tumour-related survival time (M). The first row represents
MSTAC for patients that received no adjuvant treatment.
For younger patients, survival rate increases at 5 and 10
years that are due to enhanced C yield greater increases in
MSTAC than those increases that are due to enhanced M.
For example, for 35 year old patients, a 20% increase in the
survival rate from breast cancer at 5 years yields a 28 year
increase in MSTAC if due to enhanced C, but only a 6 year
increase if due to enhanced M. It is important to note that
non-parametric survival methods cannot distinguish between
these two mechanisms for enhancing survival rate.
Figure 2 shows variations in values of MSTAC when the
loglogit or Weibull functions are substituted for the lognor-
mal function in the model of tumour-related survival. It is
apparent from this figure that the function selected has
relatively little impact on these values.
Discussion
As noted in the Introduction above, we rely primarily on
controlled clinical trials to select the optimum adjuvant
therapy for patients with stage 2 breast cancer. We generally
make our selection within 5 to 10 years after treatment, using
a non-parametric method to determine which group has the
best survival rate. Hidden within this process, however, is an
unspoken assumption: That treatment which yields the best
short-term survival rate will also yield the best long-term
clinical course. Unfortunately, we now have several reasons
to call this assumption into question.
(1) An earlier study revealed that, with limited follow-up,
an increase in cured fraction is more difficult to detect
by the log rank test than a comparable increase in
median tumour-related survival time (Gamel et al.,
1993).
(2) We cannot rely on differences in the survival rate at an
early endpoint to determine which treatment yields the
largest cured fraction (Figure 1).
(3) The long-term clinical impact of an early increase in
survival rate is highly sensitive to the mechanisms
involved; treatment that enhances cured fraction has a
substantially greater long-term impact than treatment
that enhances median tumour-related survival time.
This is especially true for younger patients (Table I).
Such sensitivity is largely independent of the particular
function selected to represent the tumour-related sur-
vival rate (Figure 2).
Taking these findings in concert, we must conclude that the
short-term survival rate is a limited measure of long-term
clinical course. Fortunately, with increasing follow-up:
(1) The log rank test becomes progressively more sensitive
to enhanced cured fraction and less sensitive to
enhanced median tumour-related survival time (Gamel
et al., 1993).
(2) Tumour-related survival rate becomes a more reliable
index of cured fraction (Figure 1).
(3) The long-term clinical impact of a specific increase in
survival rate becomes less sensitive to cured fraction
(Table I).
Unfortunately, the clinical exigencies of adjuvant therapy
argue for the shortest possible follow-up. Trials are very
expensive, and we want to offer the best treatment to all
patients as soon as possible. In seeking to resolve this
dilemma, we should give careful consideration to two impor-
tant issues:
Patient age
The findings shown in Table I suggest that older patients
enjoy less benefit from therapy than younger patients. Fur-
thermore, because of the greater likelihood of death from
other causes, older patients provide less follow-up data with
which to evaluate therapeutic effect.
Duration offollow-up
We do not have sufficient evidence to justify a radical
revision of the protocols for clinical trials. For the
foreseeable future, we will continue using non-parametric
methods to detect an early separation in survival curves.
Nevertheless, these protocols could allow for a 'second look'
at some predetermined time (e.g., 5 or 10 years) beyond the
traditional 'first look'. Such a second look would demand
relatively little additional expenditure - specifically, the
money required to maintain follow-up surveillance for the
additional time interval. Given the initial investment, and
given the long-term costs of an erroneous early conclusion,
such a cautionary measure would seem to justify the cost.
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